Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers.  It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
It was designated as a breakthrough therapy for breast cancer by the US Food and Drug Administration (FDA) in October 2015.
In September 2017, it was approved for use in the United States by the FDA for the treatment of certain breast cancers.